)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Brii Biosciences
Brii Biosciences (2137) investor relations material
Brii Biosciences H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary21 Aug, 2026
Executive summary
Advanced HBV functional cure portfolio with new Phase 2b data from ENSURE, ENRICH, and ENHANCE studies, supporting combination approaches and informing Phase 3 design; longer-term follow-up ongoing with more data expected in H2 2026.
Initiated first clinical study of BRII-5395, an internally developed mRNA therapeutic vaccine for advanced hepatocellular carcinoma, marking a milestone for internal RNA-based discovery.
Continued investment in RNA-based technology platforms and early-stage pipeline, expanding into new therapeutic areas beyond infectious diseases.
Actively seeking external partnerships to optimize resource allocation and maximize non-core asset value, including for HIV and MDR programs.
Arbitration with Vir Biotechnology ongoing since April 2026, impacting timing and development of Phase 3 HBV/elebsiran-containing combination studies.
Financial highlights
Research and development expenses decreased by 16.0% year-over-year to RMB98.3 million, mainly due to lower employee and third-party contracting costs.
Administrative expenses fell by 9.6% year-over-year to RMB52.6 million, primarily from reduced employee costs.
Other income dropped by 30.6% year-over-year to RMB19.5 million, mainly due to lower bank interest income.
Other gains and losses increased to RMB30.5 million, driven by changes in fair value of equity investments.
Loss for the period attributable to owners was RMB101.0 million, a 32.1% decrease year-over-year; basic and diluted loss per share improved to RMB0.14.
Cash and cash equivalents at June 30, 2026, were RMB1,770.8 million, down 8.8% from RMB1,941.0 million at year-end 2025.
Outlook and guidance
Focus remains on advancing HBV and RNA-based platforms, with a diversified pipeline and sustainable innovation as key goals.
Phase 3 HBV program contingent on resolution of ongoing arbitration with Vir Biotechnology and full clinical data; further development path to be evaluated in H2 2026.
Cash reserves expected to fund planned development and operations through 2029.
Unutilized IPO proceeds to be used by end of 2027, aligned with pipeline and business needs.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Brii Biosciences
- Advancing novel HBV, HIV, and antibiotic therapies with promising clinical progress.2137
Corporate presentation - First revenue achieved, net loss halved, and HBV clinical and discovery programs advanced.2137H2 2025
- Loss narrowed 47.5% as HBV cure programs advanced and cash reserves remained strong.2137H1 2025
- HBV cure programs progress, costs fall, but net loss widens; cash supports operations through 2027.2137H1 2024
- HBV cure programs advance as cash runway extends beyond 2028.2137H2 2024
Next Brii Biosciences earnings date
H2 202619 Mar, 2027
Brii Biosciences
Next Brii Biosciences earnings date
H2 202619 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Brii Biosciences Limited is a biotechnology company focused on developing therapies for infectious diseases and central nervous system disorders. The company specializes in innovative treatments for conditions such as hepatitis B, HIV, and drug-resistant bacterial infections. It leverages partnerships with global research institutions and biopharmaceutical firms to advance its pipeline through clinical development and regulatory approval. The company is headquartered in Beijing, China, and its shares are listed on the Hong Kong Stock Exchange (HKEX).